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Abstract: The risk of osteoporosis and cardiovascular disease increases significantly in
postmenopausal women. Until recently, the underlying mechanisms have been
primarily attributed to estrogen decline following the menopause. However, FSH levels
rise sharply during menopausal transition and are maintained at elevated levels for
many years. FSHR has been detected in various extragonadal sites, including
osteoclasts and endothelial cells. Recent advances show that FSH may also contribute
to postmenopausal osteoporosis and cardiovascular disease. We review here the key
actions through which FSH could contribute to osteoporosis and cardiovascular
disease in women transitioning through the menopause. Advancing our understanding
of the precise mechanisms through which FSH promotes osteoporosis and
cardiovascular disease may provide new opportunities for improving quality of life for
postmenopausal women.
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School of Basic Sciences, Guangzhou Medical University 
Laboratory of Molecular Endocrinology 
 
 
Guangzhou, 03.06.2018 
To Editor-in-Chief, 
Trends in Endocrinology and Metabolism 
 
Dear, Dr Beymer 
 
We are extremely grateful for your prompt dealing with our manuscript entitled ‘Extragonadal effects of FSH on 
osteoporosis and cardiovascular disease in women’. We thank the reviewer and the editor very much for their 
constructive comments on our manuscript. In light of these comments we have made amendments and prepared a 
revised manuscript. This has entailed editing and adding new text and figures, with changes highlighted in red. We 
have listed each of the reviewer’s and the editor’s comments and provided our detailed response.  
 
We believe our manuscript is much improved and we hope that it is now considered suitable for publication in TEM. 
 
Yours sincerely, 
 
On behalf of the authors, 
 
Prof. Xiaodong Fu 
 
Xiaodong Fu, MD., Ph.D. 
 
Professor,  
Director of Laboratory of Molecular Endocrinology, 
Department of Physiology, School of Basic Sciences 
Guangzhou Medical University 
195 Dongfeng Xi Road, 510180  
Guangzhou, CHINA 
Tel: +86.20.81340754 
E-mail: fuxiaod@gzhum.edu.cn; fuxiaodong27@hotmail.com  
Cover Letter
Authors’ response to the editor and the reviewer’s comments：TEM-D-18-00111 
 
EDITORIAL COMMENTS: 
 
OVERALL ASSESSMENT  
Very interesting insights on the role of FSH in osteoporosis and cardiovascular disease risk. 
Will appropriate revisions it will be a good resource for the broad readership of TEM. 
Authors’ response: 
We thank the editor for such positive comments on our manuscript. 
 
LENGTH  
Currently at a length of ~2100 words, being on the shorter side of TEM reviews. Thus in 
addressing the reviewer comments, the main text can be expanded to between 3500 and 4000 
words (final) if needed. 
Authors’ response: 
We have revised and expanded our manuscript according to the editor’s and the reviewer’s 
comments. The length of our revised manuscript is ~2800 words. 
 
CLARITY/ACCESSIBILITY 
Please review the changes I have suggested in the main text and make any modifications 
necessary if the intended scientific meaning has been altered.  
Authors’ response: 
We thank the editor’s comments on our main text and we have made amendments 
accordingly.  
 
Editor comment 1: 
It is well know that Estrogen is a negative regulator of FSH secretion, is there evidence that 
the menopausal decline in E2 is not the main causative factor of elevated FSH levels in 
menopause? 
Authors’ response: We thank the editor for this comment. In addition to Estrogen, the 
glycoprotein hormone inhibin A and inhibin B have also been shown to suppress the 
production of FSH in a manner of negative feedback [ref 20, 21 in the main text]. Indeed, 
previous studies have shown that both decreased levels of estrogen and inhibins contribute to 
the elevated levels of FSH during the menopause transition [1]. We have included additional 
text in our revised manuscript as below (page 19, box 1, line 11-12). 
 
“In addition, previous studies have shown that inhibin A and B also inhibits the production of 
FSH in a manner of negative feedback [20, 21].” 
 
Editor comment 2: 
This is only needed after the first glossary word. 
Authors’ response: We have removed them in our revised manuscript, except the first 
glossary word. 
 
Response to Reviewers
 Editor comment 3: 
Is there any information on the dynamics of the changes does FSH rise before the drop in 
estrogen levels? 
Authors’ response: We thank the editor for this comment. Previous studies have shown that 
FSH rises before the drop in estrogen levels during menopausal transition [ref.2 in the main 
text]. We have included a new introduction section in our revised manuscript (page 3-4, line 
61-96). In the introduction, we have provided detailed information about hormonal changes in 
women with menopausal transition and statistics regarding incidence of rates of osteoporosis 
and CVD in pre- vs post-menopausal women. We have also provided figure 1 for 
demonstrating FSH rises before estrogen.  
 
“Introduction 
During menopausal transition, women undergo irregular menstruation or infrequent menses, 
with the permanent cessation of menstrual cycle due to depletion of viable follicles [1]. The 
length of menopausal transition is highly variable, ranging from 3-9 years in women aged 
around 45–55 years old. Menopausal transition is associated with alterations in hormone 
profiles. The two well established hormonal profiles are (1) a marked decline in estrodial and 
(2) a notable rise in follicle-stimulating hormone (FSH). The Study of Women's Health Across 
the Nation (SWAN), the most comprehensive U.S. study to date, followed premenopausal 
women over the menopause transition. Previous studies examined 1,215 SWAN participants 
who transitioned through the menopause over time and reported that FSH levels increased as 
early as 6 years before the final menstrual period (FMP) and stabilized 2 years after the FMP. 
Estrogen levels declined until 2 years before the FMP and stabilized after 2 years around the 
FMP [2] (Figure 1). Across the menopausal transition, serum levels of FSH increased from 
15.15 mIU/mL to 98.21 mIU/mL, while serum levels of estrodial dropped from 60.26 pg/ml 
to 19.12 pg/ml [2].  
 
Osteoporosis is defined as a skeletal disease with a significant reduction in bone mineral 
density and an associated increased risk of bone fracture [3]. Menopause is widely recognized 
as a risk factor for osteoporosis and bone fracture in women’s later life. It has been reported 
that bone loss accelerates during the late stage of menopausal transition and continues into old 
age [4-6]. A large cohort of UK women study has shown that the relative risk (RR) of hip 
fracture in postmenopausal women is significantly higher than in premenopausal women with 
similar age (adjusted RR 2.22, 95% confidence interval [CI] 1.22–4.04; p = 0.009) [7]. 
Menopause is also thought to be a risk factor for cardiovascular disease in women. The 
Framingham Heart Study reported that postmenopausal women aged 50–59 years had 4 times 
the 10-year incidence of coronary heart disease as premenopausal women of similar age, but 
results were not adjusted for age or smoking [8]. The Nurses’ Health Study reported that 
women who had undergone bilateral oophorectomy showed an increased risk of coronary 
heart disease compared to premenopausal women (rate ratio, 2.2; 95 percent confidence limits, 
1.2 and 4.2) [9]. Interestingly, recent studies have reported elevated risk factors for 
cardiovascular disease including body fat composition [10], lipids and lipoprotein [11], and 
vascular remodeling [12-13] in women transitioning though the menopause. Increased 
susceptibility to osteoporosis and cardiovascular disease in postmenopausal (see Glossary) 
women may be associated with changes in their hormone levels.”  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Ovarian hormonal changes in perimenopause. With transition into menopause, 
FSH increases markedly and estrogen declines. In postmenopausal women, estrogen levels 
are low, and FSH levels remain high for several years [2]. This graph is intended to show the 
trends of changes in FSH and Estrogen levels and do not stand for absolute amounts. 
 
Editor comment 4: 
We encourage you to contribute any of these optional features along with your revised 
manuscript: 
Figure360 video: Create a narrated, animated version of one of your figures that helps the 
reader zoom in on the most important take-home message in two minutes or less. The video 
should contain data and panels from only one figure, and include minimal introduction. For 
further guidelines and examples, please click here. 
Interactive Questions (IQ): Use our online “Interactive Questions” tool to create a brief 
multiple-choice quiz, based on your review, that will be presented to readers alongside the 
published article as an interactive quiz to test their knowledge. 
Authors’ response: A Figure360 video for Figure 4 is provided in our revised manuscript, 
which demonstrates the potential mechanisms through which FSH increases the risk of 
cardiovascular disease in women. 
 
REVIEWER COMMENTS:  
Reviewer #1: 
I strongly support the publication 
Authors’ response: We thank the reviewer for such positive comments on our manuscript. 
 
Reviewer #2:  
The present manuscript article by Zhu et al. presented a brief overview of the extragonadal 
actions of FSH specifically related to its actions in bone and the cardiovascular system. This 
review is timely given the recent publications in mice models indicating that the rise in FSH, 
rather than the decline in estradiol, may contribute to adiposity and loss of bone. Overall, the 
article succinctly presents most of the leading evidence in this newly emerging field. The 
article is mostly well written, although some re-organization and editing for clarity and 
English are warranted as detailed below. One major limitation to the article in its current form 
is the tone that FSH undoubtedly plays a primary role in the development of osteoporosis and 
cardiovascular disease, when in fact, most research in this area has been conducted in animal 
or cell models, with little prospective evidence of translation across species, including 
humans. In fact, a recent review article regarding the extragonadal actions of FSH authored 
by T. Raj Kumar, a leading expert in the field concludes, "Human studies are currently 
controversial, and definitive answers are yet to come. If the extragonadal action of FSH is 
also confirmed in humans, novel therapeutic opportunities for treating postmenopausal 
osteoporosis and increased adiposity will be feasible." (Kumar TR. Endocrinology, 2018, 
159(1):2-8). Thus, the state of the field remains somewhat unsettled. Much of this uncertainty 
is resultant to the inability of independent research groups to reproduce some of the studies 
reporting the detection of the FSH receptor (FSHR) in extragonadal tissues. Thus, the 
extragonadal distribution of FSHR, and if all extragonadal actions of FSH occur exclusively 
through FSHR, remain uncertain, especially in humans. Our comments below are broken into 
General (comments that apply to many sections of the paper and will not necessarily be 
pointed out at each individual instance) and detailed comments. 
General Comments: 
1) Throughout the manuscript, the FSHR is referred to as the sole receptor for FSH. This is 
not necessarily known as an absolute truth and should be tempered throughout the paper. 
2) Manuscript could be structured better so that it is easy to follow. 
3) Authors need to be careful referring to data in rodents as postmenopausal osteoporosis or 
CVD because rodents don't go through menopause. The model used (e.g., ovariectomy) 
should be stated and described as a model of menopause. 
Authors’ response: 
We thank the reviewer for their comments. In our revised manuscript, we have made 
amendments accordingly. These includes:  
(1) We have referred to FSHR as the receptor of FSH. 
(2) We have re-structured our manuscript accordingly. 
(3) We have revised our manuscript accordingly and the rodent models are stated and 
described across our manuscript where necessary.  
 
Detailed Comments: 
1) Highlights - 
a. #5 - FSH represents a [potential] novel therapeutic target for the treatment of 
postmenopausal osteoporosis and CVD. 'Potential' should be added to this statement, because 
more research is needed before it is certain of its potential utility in humans. 
Authors’ response: We have added ‘potential’ in our revised manuscript (Highlights, line 
11-12). 
 
“FSH represents a potential novel therapeutic target for the treatment of postmenopausal 
osteoporosis and cardiovascular disease.” 
 
 
2) Abstract - 
a. Line 4 - Editing for English: "However, follicle stimulation hormone[s] levels rise sharply 
during the menopausal and [are maintained] at elevated levels for many years. 
Authors’ response: We have amended this sentence in our revised manuscript (page 2, line 
35-36).  
 
“However, follicle-stimulating hormone (FSH) levels rise sharply during menopausal 
transition and are maintained at elevated levels for many years.” 
 
b. Line 5 - Remove the phrase “sole receptor for FSH” 
Authors’ response: We have removed the phrase ‘sole receptor for FSH’through our revised 
manuscript.  
 
c. Line 9 - "We review here the key actions of FSH in postmenopausal women and discuss 
underlying mechanisms". This review is really not specific to postmenopausal women per se, 
thus, suggest that this be tempered and say either just women, or "We review here the key 
actions by which FSH could contribute to the development of osteoporosis and CVD in 
women as they transition through menopause. - This same comment can be made about the 
title 
Authors’ response: We have amended our text in the abstract as below (page 2, line 38-40).  
 
“We review here the key actions by which FSH could contribute to the development of 
osteoporosis and cardiovascular disease in women as they transition through menopause.” 
 
We have amended our title as below (Page 1, line 1). 
 
“Extragonadal effects of follicle-stimulating hormone on osteoporosis and cardiovascular 
disease in women with menopausal transition.” 
 
d. Line 11 - "disease may provide new opportunities for improving [quality of life] for 
postmenopausal women. 
Authors’ response: We have corrected it as below (page 2, line 43). 
 
“….disease may provide new opportunities for improving quality of life for postmenopausal 
women.” 
 
3) Introduction - 
a. An introduction is needed to set up the manuscript. The intro could contain details on how 
sex hormones change across the menopausal transition including a figure that demonstrates 
how FSH rises before estradiol declines during early perimenopause and how FSH stays high 
and E2 low postmenopause. 
Authors’ response: We agree with the reviewer’s comments. We have included an 
introduction section and a figure in our revised manuscript (page 3-4, line 61-96). 
 
b. Inclusion of statistics regarding incidence of rates of osteoporosis and CVD in pre- vs 
post-menopausal women could be used here to highlight the importance of the problem. 
Authors’ response: We thank the reviewer for their suggestion. We have now included 
statistics regarding incidence of rates of osteoporosis and CVD in pre- vs post-menopausal 
women in our revised manuscript (page 3-4, line 82-96). 
 
“A large cohort of UK women study has shown that the relative risk (RR) of hip fracture in 
postmenopausal women is significantly higher than in premenopausal women with similar 
age (adjusted RR 2.22, 95% confidence interval [CI] 1.22–4.04; p = 0.009) [7]. Menopause is 
also thought to be a risk factor for cardiovascular disease in women. The Framingham Heart 
Study reported that postmenopausal women aged 50–59 years had 4 times the 10-year 
incidence of coronary heart disease as premenopausal women of similar age, but results were 
not adjusted for age or smoking [8]. The Nurses’ Health Study reported that women who had 
undergone bilateral oophorectomy showed an increased risk of coronary heart disease 
compared to premenopausal women (rate ratio, 2.2; 95 percent confidence limits, 1.2 and 4.2) 
[9]. Interestingly, recent studies have reported elevated risk factors for cardiovascular disease 
including body fat composition [10], lipids and lipoprotein [11], and vascular remodeling 
[12-13] in women transitioning though the menopause. Increased susceptibility to 
osteoporosis and cardiovascular disease in postmenopausal (see Glossary) women may be 
associated with changes in their hormone levels.” 
 
4) The role of FSH in gonadal development and beyond 
a. Second paragraph, pg 3 - also need to state that other investigators have not been successful 
in reproducing the original experiments conducted in HUVECs (e.g., Stelmaszewska et al did 
not find FSHR expression in HUVECs, nor did FSH treatment show effects on tube formation, 
NO production, wound healing or proliferation in HUVECs.) 
Authors’ response: We thank the reviewer for their comments. We are sorry for not including 
these information in our original manuscript due to the limit of references numbers requested 
by the Journal. We have included new text in our revised manuscript (Page 4, line 113-118). 
 
“A number of reports have recently demonstrated that it is also expressed in a range of 
extragonadal sites, including human osteoclasts [31] and monocytes [32], tumor vasculature 
and metastases [33], the liver [34] and human umbilical vein endothelial cells (HUVECs) [35, 
36], although other independent investigators have not been successful in reproducing the 
original experiments conducted in HUVECs [37].” 
 
b. Second paragraph, pg 3, 4rth sentence from the bottom "The decline in estrogen across the 
period of menopausal transition…" needs references to support this statement. 
Authors’ response: References have been added into our revised manuscript [ref 38, 39] 
(page 5, line 123). 
 
5) FSHR mutations and their clinical consequences (page 4 and table 1) 
a. This section should be linked to extragonadal tissue response, pathophysiology/disease, if 
not, suggest that this should be removed. 
b. Table 1 - link the "Phenotype of subjects" column with extragonadal consequences of these 
phenotypes. 
c. Line 8 - "have demonstrated that each motif plays an important role in FSHR 
function…(box2)..." The description in Box 2 describes FSHR signaling cascades, but does 
not appear to discuss how different mutations impact signaling through these cascades. Please 
clarify. 
Authors’ response: We thank again for the reviewer’s comments. All the functional studies 
for these mutations in this section were performed in HEK293 cells or granulosa cells. These 
mutations are not associated with extragonadal tissue response, pathophysiology/disease, 
therefore we have removed this section for our revised manuscript. 
 
6) FSH enhances bone resorption in postmenopausal women (page 5) 
a. This subheading is somewhat misleading as the evidence presented does not actually detail 
how FSH enhances bone resorption in postmenopausal women per se. A more appropriate 
subheading could be "FSH and the risk for osteoporosis" 
Authors’ response: We agree with the reviewer’s comments. We have amended the 
subheading for this section (page 5, line 129). 
 
“FSH and the risk for osteoporosis” 
 
b. Paragraph 1, Line 1 - "Osteoporosis is characterized by an absolute reduction in BMD and 
an associated risk for bone fractures" Reference needed. 
Authors’ response: The reference has been added in our revised manuscript [ref 3] (page 2, 
line 79).  
 
c. Paragraph 1, Line 3 - "Estrogen deficiency has [long] been considered [for long] as a major 
contributor of postmenopausal osteoporosis" Also needs reference. 
Authors’ response: We have amended our text (page 5) and included the reference in our 
revised manuscript [ref 40] (page 5, line 132). 
 
“Estrogen deficiency has long been considered as a major contributor of postmenopausal 
osteoporosis [40].” 
 
d. Paragraph 1, Line 4 - The sentence that being with "However, studies have revealed that 
nearly half…" is unclear. This sentence needs to be restructured and/or peri-menopause needs 
to be better defined in the Glossary. This text refers to Box 3, which describes the hormonal 
alterations in estrogen and FSH across the menopausal transition, but including this 
information in the introduction with a figure (that is referred to here) would be more clear. 
Authors’ response: We have included an introduction section and a figure for our revised 
manuscript (page 3-4, line 61-96). We have restructured the sentences (page 5, line 132-137) 
and re-defined peri-menopause in Glossary (page 21, line 12). 
 
“However, it has been reported that bone loss occurs around 2–3 years before the FMP [41], 
when estrogen levels are relatively normal while FSH levels are significantly elevated (Figure 
1). In addition, previous cross-sectional [42] and longitudinal [43] studies have shown that 
higher serum FSH levels but not lower serum estradiol levels are associated with lower bone 
mineral density among pre- and early perimenopausal women enrolled in SWAN.” 
 
Glossary 
 
“Perimenopause (STRAW +10 Staging System: stage -2 to +1a): the time around menopause 
and begins at Stage –2 and ends 12 months after the final menstrual period (Stage +1a).” 
 
e. Paragraph 2 - When citing references 45 and 47, the statements do not indicate what the 
outcomes may be adjusted for (such as education, physical activity level, diet, etc.). These 
adjustments are detailed in the results sections of the references papers. 
Authors’ response: We thank the reviewer for consideration of this point. We have amended 
our text to include these adjustments (page 5-6, line 142-155).  
 
“A small cohort study has shown that women with hypergonadotropic amenorrhea (mean 
FSH>40 mIU/mL) have lower lumbar spine bone density than those with hypogonadotropic 
amenorrhea (mean FSH<40 mIU/mL), with comparable estrogen levels between the two 
groups. In addition, only FSH levels were negatively correlated with lumbar spine bone 
density in hypergonadotropic amenorrheic women, after adjustment for age and body mass 
index (BMI) [44]. Furthermore, previous studies investigated 2,375 pre and early 
perimenopausal women from SWAN and found that higher FSH concentrations were 
associated with elevated concentrations of the bone resportion marker urinary N-telopeptide 
of type I collagen (NTx), after adjustment for BMI, thyroid disease, insulin sensitivity, 
difficulty in paying for basics, race/ethnicity, seasonality and site. Higher FSH concentrations 
were also associated with higher osteocalcin concentrations (bone formation maker), after 
adjustment for smoking, physical activity, physical functioning, BMI, diabetes, insulin 
sensitivity, thyroid disease, race and site [45].” 
 
f. Paragraph 2, line 5 - Sentence that begins with "Interestingly, postmenopausal women with 
an activating FHSR polymorphism…" seems out of place in this section. Would make more 
sense in the section about FSHR mutations. This is also an example of what could be included 
in the FSHR mutation section to link the mutation with extragonadal consequences. 
Authors’ response: We have removed the FSHR mutation section in our revised manuscript. 
 
g. Paragraph 2, line 6 - Sentence that begins with "Furthermore, a cross-sectional study of 
2,375 peri-menopausal women…" is misleading. Authors state evidence for bone turnover, 
but only present data regarding bone resorption. Were bone formation markers measured and 
reported in the original paper? If so, they need to be included in this sentence or bone 
turnover needs to be changed to bone resorption. 
Authors’ response: We are sorry for not including bone formation markers in our original 
manuscript. We have amended the text in our revised manuscript (page 5-6, line 147-155). 
 
“Furthermore, previous studies investigated 2,375 pre and early perimenopausal women from 
SWAN and found that higher FSH concentrations were associated with elevated 
concentrations of the bone resportion marker urinary N-telopeptide of type I collagen (NTx), 
after adjustment for BMI, thyroid disease, insulin sensitivity, difficulty in paying for basics, 
race/ethnicity, seasonality and site. Higher FSH concentrations were also associated with 
higher osteocalcin concentrations (bone formation maker), after adjustment for smoking, 
physical activity, physical functioning, BMI, diabetes, insulin sensitivity, thyroid disease, race 
and site [45].” 
 
h. Paragraph 2, line 10 - Sentence beginning with "Further studies have shown that FSH 
levels are positively correlated with bone resorption…" only includes data for CTX, but the 
paper also reported osteocalcin. Why was only CTX included in this statement? This sentence 
might also better fit in the next paragraph since that paragraph focuses on the imbalance 
between formation and resorption. Also the end of the sentence states "postmenopausal 
healthy women and menopausal transition women" these phrases need to be edited for word 
order and correct term use. 
Authors’ response: We thank the reviewer for their comments. We agree with the reviewer 
that it fits better in the next paragraph. We have amended our text and moved it to the next 
paragraph (page 6-7, line 180-185).  
 
“Interestingly, further studies have shown that serum levels of FSH are positively correlated 
with the bone resorption marker CTX and the bone formation marker osteocalcin in healthy 
postmenopausal women [57], indicating a potential role of FSH in bone turnover. In addition, 
a significantly positive association between FSH and CTX has also been reported in 
osteoporotic Chinese women during the menopausal transition [58].” 
 
 
i. Paragraph 3, line 1 - needs reference 
Authors’ response: The reference has been added [ref 49] (page 6, line 164). 
 
j. Paragraph 3, line 8 - what is meant by "conceptive studies"? 
Authors’ response: We are sorry for the mistake. We have amended our text (page 6, line 176). 
 
“several studies have been performed to test whether the specific inhibition of FSH can prevent 
ovariectomy-induced bone loss in mouse models.” 
 
 
k. Paragraph 3 - References 58 and 59 are from mice, but this is not explicitly stated. Please 
indicate that this is not human data. 
Authors’ response: We thank the reviewer for consideration of this point. We have clearly 
stated these data are from mice in our revised manuscript (page 6, line176-180). 
 
“several studies have been performed to test whether the specific inhibition of FSH can prevent 
ovariectomy-induced bone loss in mouse models. Indeed, blocking FSH with a specific antibody 
targeting its β-subunit increases bone mass and reduces body fat in mouse models [55, 56].” 
              
7) FSH increases the risk of cardiovascular disease in postmenopausal women 
a. We suggest that the heading be changed to "FSH and the risk for cardiovascular disease" 
Authors’ response: We have amended the subheading title for this section (page 7, line 188). 
 
“FSH and the risk for cardiovascular disease” 
 
b. Paragraph 1, line 4 - The section of this paragraph starting with "Interestingly, epidemiological 
studies have shown that estrogen replacement therapy…" is confusing and the transition 'however' 
appears to be misused. The clinical trial data showed harm in women who were 20+ years 
postmenopause. 
Authors’ response: We thank the reviewer for their comments. We have amended the text in 
our revised manuscript (page 7, line 192-200).  
 
“Whether estrogen replacement therapy could reduce cardiovascular disease remains 
ambiguous. Previous studies have shown that estrogen replacement therapy at standard daily 
dose of 0.625mg or less decreases cardiovascular disease risk in postmenopausal women 
without previous history of heart disease. However, estrogen at a higher daily dose of 
0.625mg or more and in combination with progestin may modestly increase the risk for stroke 
[60, 61]. Recent clinical trials have demonstrated that menopausal hormone therapy for 5 to 7 
years is not associated with risk of all-cause, cardiovascular, or cancer mortality among 
27,347 postmenopausal women aged 50 to 79 years during a cumulative follow-up of 18 
years [62].” 
 
c. Paragraph 1, line 9 - If a figure showing the FSH/estrogen changes over the menopausal 
transition is included, it could be referenced at the end of the sentence starting with "In 
contrast to the decline in estrogen levels observed during menopause.." 
Authors’ response: We have included figure 1 in our revised manuscript and referred to it 
here (page 7, line 202). 
 
d. Paragraph 1, line 13 - Include what the outcomes were for determining "subclinical 
atherosclerosis" (e.g., coronary artery calcium, carotid IMT). 
Authors’ response: We have amended our text and include these information (page 7, line 
203-206). 
 
“Several previous studies have examined associations between FSH levels and subclinical 
atherosclerosis including coronary artery calcium and the carotid intima-media thickness 
(IMT) in women, with the majority of them reporting a positive correlation [63-65].” 
 
e. Paragraphs 2 & 3 - The mechanisms linking FSH and CVD need to be more clearly 
organized/listed so that it is easy to read. We suggest breaking it into paragraphs or sections that 
focus on adiposity, angiogenesis, lipids, calcification, and endothelial activation with a bit more 
detail in each section. Right now, the section on endothelial cell activation is highly detailed, while 
just a sentence or two are dedicated to each other mechanism listed. If the preference of the 
authors is to keep the emphasis on endothelial cells as a primary mechanism, then we suggest 
moving paragraph 3 ahead of paragraph 2. 
Authors’ response: We thank the reviewer for their suggestions and we agree this section 
should be restructured. We have broken this section into several paragraphs (page 8-10, line 
218-280). 
 
“Potential mechanisms by which FSH increases risk of cardiovascular disease 
FSH may increase risk of cardiovascular disease through a number of distinct mechanisms 
(Figure 4):  
Effects of FSH on endothelial cell activation and atherosclerosis 
Endothelial cell activation by oxidized lipids and pro-inflammatory stimuli plays an important 
role in the initiation and progression of atherosclerosis. Activated endothelial cells express a 
variety of adhesion molecules such ICAM-1 and VCAM-1, which recruits leukocytes to the 
endothelium [68]. Our recent report demonstrated for the first time that FSH directly 
accelerates atherosclerosis in ovariectomized ApoE-/- mice, independent of estrogen 
deficiency. Mechanistically, FSH up-regulated VCAM-1 expression in human umbilical vein 
endothelial cells and subsequently increased human monocyte adhesion through 
FSHR/Gαs/cAMP/PKA and PI3K/Akt/mTOR/NF-κB signaling pathways. Interestingly, 
FSHR was specifically localized in caveolae of endothelial cells. Caveolin-1, the main protein 
component of caveolae, directly interacted with FSHR and mediated its downstream signaling 
actions [36].  
 
FSH accelerates adiposity and lipid accumulation 
Cui et al recently reported that FSH treatment increases the weight of abdominal fat and lipid 
accumulation of adipocytes in chickens, through enhancing the expression of genes in the 
fatty acid metabolism pathway, retinol metabolism pathway, and peroxisome 
proliferator-activated receptor (PPAR) signaling pathway [69]. Further studies showed that 
FSHR was functionally expressed in human and mouse fat tissues and adipocytes. FSH 
treatment increased lipid biosynthesis, lipid droplet formation, altered the secretion of leptin 
and adiponectin through the Gαi/Ca2+/CREB pathway in mouse 3T3-L1 preadipocytes [70]. 
Interestingly, recent elegant studies performed by Liu et al have shown that blockade of FSH 
signaling with a specific antibody reduces high-fat diet-induced obesity in wild type mice and 
adiposity in ovariectomized mice [55]. Specifically, antibody-treated mice showed 
significantly reduced total (TFV), subcutaneous (SFV) and visceral fat volume, but 
interscapular brown adipose tissue remained unchanged [55]. These data suggest that FSH 
may play an important role in determining body fat distribution, which may contribute to 
cardiovascular dysfunction [71]. Interestingly, it has been shown that serum FSH levels are 
positively associated with serum total cholesterol and LDL-C levels in Chinese 
postmenopausal women [34]. FSH administration in ovariectomized mice promotes 
dyslipidemia through inhibiting hepatic cholesterol metabolism. Mechanistically, FSH 
reduces LDLR levels in hepatocytes and attenuates the endocytosis of LDL-C, leading to an 
elevated circulating LDL-C level [34], which is an independent risk factor for atherosclerosis. 
Taken together, these studies suggest that FSH may increase risk factors for cardiovascular 
disease through accelerating adiposity and lipid accumulation. 
FSH promotes angiogenesis 
Angiogenesis inhibition through the application of endostatin or TNP-470 has been shown to 
decrease plaque formation and intimal neovascularization in ApoE-/- mice [72]. FSH signaling 
through FSHR in HUVECs promotes angiogenesis, which is independent of VEGF [73]. 
Interestingly, treatment of HUVECs with FSH stimulated the PI3K/AKT signaling pathway, 
with similar efficacy as VEGF [73]. These data suggest that FSH may increase atherosclerosis 
through promoting angiogenesis. However, the effect of FSH on angiogenesis cannot be 
reproduced by other investigators and the discrepancy remains to be clarified [37]. 
 
Potential role of FSH in vascular calcification.  
Vascular calcification is a common feature of advanced atherosclerosis and is important in 
determining atherosclerotic plaque stability [74]. We and others have previously demonstrated 
that vascular calcification shares many similarities to bone remodeling, which involves 
maintaining a balance between osteoblasts and osteoclasts [75-77]. The presence of 
osteoclast-like cells and active resorption of ectopic mineral deposition have been reported in 
calcified atherosclerotic plaques [78]. Furthermore, monocytes and macrophages are 
frequently observed in atherosclerotic plaque [79]. These data suggest that osteoclasts, 
through a signaling cascade involving FSH (Figure 3) may be recruited to calcified regions 
where they can resorb mineral deposition, subsequently increasing the incidence of plaque 
rupture [80] (Figure 4). In addition, FSH stimulates immune cells to release inflammatory 
cytokines [53, 54], which may also contribute to vascular calcification (Figure 4). ” 
 
 
f. Paragraphs 2 & 3 - Check this section to make sure it is clearly state which results are from 
clinical versus mouse versus cell studies. 
Authors’ response: We thank the reviewer for their comments. We have clearly indicated 
which results are from clinical versus mouse versus cell studies in our revised manuscript.  
 
g. Paragraph 2 - Although increased adiposity is touched on briefly as a potential mechanism 
for increased CVD risk, the importance of body fat distribution is not addressed. The 
referenced study by Liu et al. reported reduced visceral adiposity after FSH antibody 
treatment in mice, but this finding is not included. Considering the potential effect of FSH in 
determining body fat distribution is an important mechanism underlying cardiovascular risk. 
Authors’ response: We thank the reviewer for their comments. We have included this point 
in our revised manuscript (page 9, line242-249).  
 
“Interestingly, recent elegant studies performed by Liu et al have shown that blockade of FSH 
signaling with a specific antibody reduces high-fat diet-induced obesity in wild type mice and 
adiposity in ovariectomized mice [55]. Specifically, antibody-treated mice showed 
significantly reduced total (TFV), subcutaneous (SFV) and visceral fat volume, but 
interscapular brown adipose tissue remained unchanged [55]. These data suggest that FSH 
may play an important role in determining body fat distribution, which may contribute to 
cardiovascular dysfunction [71].” 
 
h. Paragraph 2, Line 17 - "Osteoclasts, through a signaling cascade involving FSH (as 
described above)…" Is this referring to the signaling cascade described in one of the boxes or 
Fig 1 (I do not see Fig 1 referenced in the text?) The reference to "above" needs clarification. 
Authors’ response: We are sorry for this confusion. This is referring to the signaling cascade 
described in Figure 3.  
Authors’ action: We have amended our text and referred to Figure 3 and Figure 4 (page 9-10, 
line 270-278). 
 
“We and others have previously demonstrated that vascular calcification shares many 
similarities to bone remodeling, which involves maintaining a balance between osteoblasts 
and osteoclasts [75-77]. The presence of osteoclast-like cells and active resorption of ectopic 
mineral deposition have been reported in calcified atherosclerotic plaques [78]. Furthermore, 
monocytes and macrophages are frequently observed in atherosclerotic plaque [79]. These 
data suggest that osteoclasts, through a signaling cascade involving FSH (Figure 3) may be 
recruited to calcified regions where they can resorb mineral deposition, subsequently 
increasing the incidence of plaque rupture [80] (Figure 4).” 
 
8) Clinical use and long-term safety on cardiovascular disease of FSH agonists 
a. Why does this section heading only refer to CVD risk and not osteoporosis risk? Even if 
there is a paucity of data, this should be addressed and included in the title. 
Authors’ response: We thank the reviewer for their comments. We have amended the title for 
this section (page 10, line 282-283). 
 
“Clinical use and long-term safety of recombinant FSH therapies against cardiovascular 
disease and osteoporosis” 
 
b. Is FSH agonist the correct term to us to refer to these recombinant FSH therapies? 
Authors’ response: We agree with the reviewer’s comments. We have changed “FSH 
agonist” to “recombinant FSH therapies” (page 10, line 293). 
 
c. Paragraph 1 - Are all of these details about recombinant FSH therapy necessary? 
Authors’ response: We thank the reviewer for the suggestion. We have removed all of these 
details about “recombinant FSH therapies” in our revised manuscript. 
 
d. Paragraph 2 should be moved before Paragraph 1. The entire paper to this point is 
discussing postmenopausal women, and then this section starts with talking about the 
different recombinant FSH therapies that are available. The initial thought is, why would a 
postmenopausal woman need FSH therapy? The second paragraph goes on to explain that 
these therapies are used in premenopausal women undergoing fertility treatments and disease 
risk has been assessed in women who have undergone these therapies. It is this paragraph that 
is of most importance in this section. With this context in mind it is easier to understand the 
content in this section 
Authors’ response: We agree with reviewer’s comments. We have removed Paragraph 1 in 
our revised manuscript. 
 9) Concluding remarks and future perspectives 
a. Line 2 - "Despite growing evidence showing that FSH accelerates osteoporosis and CVD in 
postmenopausal women…" This statement needs to be tempered. There are no direct data in 
humans that show that FSH accelerates osteoporosis and CVD. There are data that suggest 
that FSH could contribute to the decline in bone health with the menopause transition. There 
are no direct data concerning CVD. 
Authors’ response: We agree with the review’s comments. We have amended our text in the 
revised manuscript (page 11, line 301-307). 
 
“Epidemiological and animal studies have revealed that FSH contributes to the decline in 
bone health in women undergoing menopausal transition. Emerging data has shown that FSH 
treatment enhances atherosclerotic plaque formation in ovariectomized AopE-/- mice [36]. 
However, our understanding of the molecular mechanisms through which FSH increases the 
risk of osteoporosis and cardiovascular disease is far from complete (see outstanding 
questions).” 
 
b. Line 5 - "Particularly, most research investigating the effects of FSH on [postmenopausal] 
osteoporosis and CVD has focused on a limited number of FSH target genes..." Where are 
these data presented in the paper? By target genes are the authors referring to signaling 
pathways? 
Authors’ response: We thank the reviewer for their comments. We have amended the text in 
our revised manuscript (page 11, line 307-309). 
 
“The vast technological advancements such as Next-Generation Sequencing will provide 
valuable new information on the molecular pathophysiology of FSH in extragonadal tissues, 
such as bone and blood vessels.” 
 
c. Line 11 - "In addition, blockade of FSH has been shown, at least in mice, to improve 
postmenopausal osteoporosis and CVD." This statement needs to be reworded. Mice do not 
undergo menopause, so stating it as improve OVX induced bone loss (or a model of 
menopause) would be more appropriate. Also, please present and reference the data that FSH 
blockage improves CVD in mice. 
Authors’ response: We thank the reviewer for their comments. We have previous shown that 
FSH treatment enhances atherosclerosis in ovariectomized AopE-/- mice [36]. We have 
amended the text in our revised manuscript (page 11, line 309-318). 
 
“Animal studies have shown that blocking FSH increases bone mass, reduces body fat and 
induces thermogenic adipose tissue. These data suggest that blocking FSH may not only be a 
potential opportunity for treating osteopososis, but also of benefit in the treatment of visceral 
fat associated diseases such as metabolic syndrome and cardiovascular disease [55]. Whether 
FSH promotes osteoporosis and cardiovascular disease in women remains to be further 
elucidated in humans. In conclusion, a fuller understanding of the molecular pathological 
roles of FSH for osteoporosis and cardiovascular disease in postmenopausal women could 
have significant importance in improving diagnosis, management and treatment of these 
major diseases.” 
 
10) Box 1 
a. Line 3 - "FSH levels are strictly controlled by the HPG axis and [the steroid] sex 
hormone[s]- mediated feedback" This needs rewording 
Authors’ response: We have amended our text (page 19, box1, line 3-4).  
 
“FSH levels are strictly controlled by the hypothalamic pituitary gonadal axis and sex 
hormone-mediated negative feedback.” 
 
b. Line 6 - "produce FH and LH, which exert[s] their primary function…" Remove the s in 
exerts. 
Authors’ response: We have amended our text (page 19, box1, line 6).  
 
“which exert their primary function in the gonads.” 
 
c. The glycosylation issue is a potentially very important one, particularly in extragonadal 
tissues. May want to consider mentioning this in the main text of the article. 
Authors’ response: We thank the reviewer for the suggestion. We have mentioned this in our 
main text of the article (page 4, line 104-105).  
 
“Similar to other glycoprotein hormones, glycosylation of FSH plays an important role in 
regulating it’s activity [15] (see Box1).” 
 
11) Box 2 
a. Are the signaling cascades mentioned in this box pertinent to specific extragonadal tissues? Are 
some specific to certain cell types in bone or the cardiovascular system? IF so, this should be 
mentioned? 
Authors’ response: We thank the reviewer for their comments. These signaling cascades are 
not pertinent to specific extragonadal tissues and not specific to certain cell types in bone and 
the cardiovascular system. These signaling cascades were reported in granulosa cells, Sertoli 
cells or HEK293 cells. Some of these signaling pathways such as ERK, AKT have also been 
reported in extragonodal cells, such as HUVECs, preadipocytes etc.  
 
b. There is a lot of detail in here without much context and the long list of Gαs-independent 
mechanisms in the middle of the box are hard to follow. Are these pathways stimulated through 
FSH interaction with FSHR or are they alternative signaling pathways for FSH outside of FSHR? 
Without referring out to the cited references, it is difficult to follow the importance of the included 
information. Would an accompanying figure lend more relevance? 
Authors’ response: We thank the reviewer for their suggestions. These signaling pathways 
are stimulated via FSH interaction with FSHR coupled with multiple different partners. We 
have amended our text and provided a new figure for FSH downstream signaling pathways 
(box2, page 20).  
“It is now well recognized that upon FSH binding, the activated FSHR triggers a number of 
intracellular signaling pathways either in parallel or sequentially. Classically, upon FSH activation, 
FSHR functionally couples to Gαs subunit and induces the cAMP/PKA signaling pathway, 
subsequently activating the cAMP regulatory element-binding protein (CREB) and modulating 
gene expression, such as aromatase and inhibin-α [24]. This canonical signaling pathway plays a 
key role for its biological actions inside granulosa cells in the ovary and sertoli cells in the testes. 
It is now clear that FSHR also involves other transduction mechanisms upon FSH binding. In 
recent years, a number of Gαs-independent transduction mechanisms have been found. It has been 
reported that FSHR also couples to Gαi [25], Gαq [26], β-arrestins [27], Adapter protein 
containing the Pleckstrin homology domain, the Phosphotyrosine binding domain, and the 
Leucine zipper motif (APPL) [28-30]. These FSHR interacting partners enable FSH to activate 
alternative signaling pathways, including those mediated by distinct kinases such as inositol 
trisphosphate (IP3), Akt and ERK1/2. This complex signaling network triggered by FSH 
fine-tunes its biological action and determines the fate of target cells (Figure 2).” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Multiple intracellular signaling pathways induced by FSH. Classically, upon 
FSH binding, the activated FSHR induces canonical Gαs/cAMP/PKA signaling pathway, 
which subsequently activates CREB and regulates target gene expression. FSHR also 
activates its downstream signaling pathways through other Gαs-independent transduction 
mechanisms mainly coupling to other Gα subunits, β-arrestin-dependent signaling, EGFR 
transactivation, and APPL1-mediated signals [20-26]. 
12) Box 3 
a. This information would fit nicely into an introduction section with an accompanying figure. 
Authors’ response: We agree with the reviewer’s comments. We have added an introduction 
section with Figure1 for our revised manuscript (page 3-4, line 61-96). 
 
b. The description of the SWAN study is longer than necessary. Although details about the 
SAWN study are pertinent, including more detailed results instead of just two spot measures 
of E2 and FSH would be informative. Particularly, detailing the time course of the change of 
both hormones over the menopausal transition would be helpful. 
Authors’ response: We agree with the reviewer’s comments. We have added an introduction 
and Figure 1 in our revised manuscript. 
13) Table 1 
a. Remove unless specific connections with extragonadal tissues (osteoporosis/CVD) are made 
Authors’ response: It has been removed in our revised manuscript. 
 
14) Glossary 
a. Including menopause, perimenopause, postmenopausal and the menopause transition is 
redundant and the definitions provided are unacceptable. The STRAW+10 criteria should be 
used and cited for all definitions (Harlow SD et al. Menopause. 2012 Apr;19(4):387-95.) 
Authors’ response: We thank the reviewer for their constructive advice. We have re-defined 
these terms using The STRAW+10 criteria (page 21, Glossary). 
 
“Menopausal transition (STRAW +10 Staging System: Stages -2 to -1) [ref. 1] 
Early menopausal transition (Stage –2): Criterias include increased variability in menstrual cycle 
length, a persistent difference of 7 days or more in the length of consecutive cycles, elevated but 
variable FSH levels, low antimüllerian hormone and antral follicle count. 
Late menopausal transition (Stage –1): Criterias include the occurrence of amenorrhea of 60 days 
or longer, elevated FSH levels greater than 25 IU/L, low antimüllerian hormone and antral follicle 
count, and vasomotor symptoms (likely). 
 
Perimenopause (STRAW +10 Staging System: stage -2 to +1a): the time around menopause and 
begins at Stage –2 and ends 12 months after the final menstrual period (Stage +1a). 
 
Postmenopause (STRAW +10 Staging System: Stage +1a, +1b, +1c, +2): The time after the final 
menstrual period. ” 
 
 
15) Figure 1 
a. Legend - "RANKL released by osteoblasts or T cells bins to RANK in monocytes and promotes 
osteoclast formation [which subsequently leads to osteoporosis]" The end of this sentence (in 
brackets) needs to be revised with more detail. Oversimplification. 
Authors’ response: We thank the reviewer for their comments. We have amended the figure 
legend with more detail for [which subsequently leads to osteoporosis] (page 22, line 570-578). 
 
“Figure 3. FSH accelerates bone resorption through increasing osteoclast formation. FSH 
directly enhances RANK expression in monocytes [50-52]. RANKL released by osteoblasts or T 
cells binds to RANK in monocytes and promotes osteoclasts formation. FSH also stimulates 
monocytes and macrophages to release inflammatory cytokines such as TNFα, IL1β and IL6 
[53-54]. These inflammatory cytokines stimulate osteoblasts and T cells to secrete RANKL, which 
promotes osteoclasts formation. Osteoclasts are the cells responsible for bone resorption, and 
osteoblasts are the cells for bone formation. Increased ration of osteclasts to osteoblasts leads to 
bone mineral loss, which may subsequently cause osteoporosis [49].” 
 
 
b. Line 4 - The use of the transition "conversely" appears to be incorrect. It should state, "FSH 
also stimulates…" because it is still describing a mechanism leading to bone resorption. 
Authors’ response: We agree the reviewer’s comments. We have amended our text 
accordingly (page 22, line 573-574). 
 
“FSH also stimulates monocytes and macrophages to release inflammatory cytokines such as 
TNFα, IL1β and IL6 [50-51].” 
 
c. The use of references may be appropriate in the figure legend. 
Authors’ response: We have included references in our figure legend (page 22). 
 
16) Figure 2 
a. Line 1 - "FSH increases the expression of VCAM-1" is this direct or through some other 
mechanism? On the figure there is no arrow directly from FSH to VCAM-1, this should be 
added if it is a direct effect. 
Authors’ response: We thank the reviewer for their comments. We have previously shown 
that FSH directly increases the expression of VCAM-1 [ref 36 in the main text]. The arrow 
has been added in Figure 4. 
 
b. Line 7 - T cells are mentioned as a cell type that FSH may stimulate to release inflammatory 
cytokines, but they are not included on the figure. 
Authors’ response: T cells have been added in Figure 4. 
 
c. The use of references may be appropriate in the figure legend. 
Authors’ response: We have included references in our figure legend (page 22). 
 
17) Outstanding questions 
a. #3 - Suggest rewording to state: Do osteoclast or vascular endothelial cell specific FSHR 
conditional knockout mice demonstrate improved bone and vascular health? 
Authors’ response: We thank the reviewer for their suggestions. We have amended our text 
in the revised manuscript (outstanding questions, line 7-8). 
 
“Do osteoclast or vascular endothelial cell specific FSHR conditional knockout mice 
demonstrate improved bone and vascular health?” 
 b. #4 - "FSH enhanced postmenopausal atherosclerosis" This statement is reaching and should 
be reworded. There is no direct evidence to support this in postmenopausal women. 
Authors’ response: We agree with the reviewer’s comments. We have amended our text in 
the revised manuscript (outstanding questions, line 9-10). 
 
“Are there any other mechanisms involved in FSH enhanced atherosclerosis in 
ovariectomized ApoE-/- mice such as induction of inflammation or foam cell formation?” 
 
c. #5 - Needs to be edited for word order. 
Authors’ response: We have amended our text in the revised manuscript (outstanding 
questions, line 11-12). 
 
“FSH blocking increases bone mass and reduces body fat in mouse models. Can these 
findings be translated into humans?” 
 
d. Other suggested outstanding questions not mentioned but could be included: 
i. Potential for FSH actions outside of FSHR 
ii. Importance of glycosylation state in FSH action in extragonadal tissues 
Authors’ response: We thank the reviewer for their suggestions. We have added these two 
points in our revised manuscript (outstanding questions, line 13-15).  
 
“Are there any potential mechanisms for FSH biological activities without binding to FSHR 
in extragonodal tissues? 
 
What are the effects of glycosylation state of FSH on its actions in extragonadal tissues?” 
Highlights:  
 
Epidemiological studies have demonstrated that FSH levels are positively associated 
with postmenopausal osteoporosis and cardiovascular disease. 
 
Besides gonadal tissues, FSHR is found to be expressed by a range of extragonadal 
sites, including osteoclasts and endothelial cells. 
 
FSH treatment stimulates osteoclast cell formation, function and survival, which are 
the cells responsible for bone resorption. In addition, FSH administration significantly 
promotes atherosclerosis in ovariectomized ApoE-/- mice by up-regulating VCAM-1 
expression in human umbilical vein endothelial cells and subsequently increasing 
human monocyte adhesion. 
 
Blockade of FSH with a specific antibody targeting its β-subunit enhances bone mass, 
reduces body fat and atherosclerosis in mouse models.  
 
FSH represents a potential novel therapeutic target for the treatment of 
postmenopausal osteoporosis and cardiovascular disease.  
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ABSTRACT:  31 
The risk of osteoporosis and cardiovascular disease increases significantly in 32 
postmenopausal women. Until recently, the underlying mechanisms have been 33 
primarily attributed to estrogen decline following the menopause. However, FSH levels 34 
rise sharply during menopausal transition and are maintained at elevated levels for 35 
many years. FSHR has been detected in various extragonadal sites, including 36 
osteoclasts and endothelial cells. Recent advances show that FSH may also contribute 37 
to postmenopausal osteoporosis and cardiovascular disease. We review here the key 38 
actions through which FSH could contribute to the development of osteoporosis and 39 
cardiovascular disease in women as they transition through the menopause. Advancing 40 
our understanding of the precise mechanisms through which FSH promotes 41 
osteoporosis and cardiovascular disease may provide new opportunities for improving 42 
quality of life for postmenopausal women. 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
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Introduction 61 
During menopausal transition, women undergo irregular menstruation or infrequent 62 
menses, with the permanent cessation of menstrual cycle due to depletion of viable 63 
follicles [1]. The length of menopausal transition is highly variable, ranging from 3-9 64 
years in women aged around 45–55 years old. Menopausal transition is associated with 65 
alterations in hormone profiles. The two well established hormonal profiles are (1) a 66 
marked decline in estrodial and (2) a notable rise in follicle-stimulating hormone (FSH). 67 
The Study of Women's Health Across the Nation (SWAN), the most comprehensive 68 
U.S. study to date, followed premenopausal women over the menopause transition. 69 
Previous studies examined 1,215 SWAN participants who transitioned through the 70 
menopause over time and reported that FSH levels increased as early as 6 years before 71 
the final menstrual period (FMP) and stabilized 2 years after the FMP. Estrogen levels 72 
declined until 2 years before the FMP and stabilized after 2 years around the FMP [2] 73 
(Figure 1). Across the menopausal transition, serum levels of FSH increased from 15.15 74 
mIU/mL to 98.21 mIU/mL, while serum levels of estrodial dropped from 60.26 pg/ml 75 
to 19.12 pg/ml [2].  76 
 77 
Osteoporosis is defined as a skeletal disease with a significant reduction in bone mineral 78 
density and an associated increased risk of bone fracture [3]. Menopause is widely 79 
recognized as a risk factor for osteoporosis and bone fracture in women’s later life. It 80 
has been reported that bone loss accelerates during the late stage of menopausal 81 
transition and continues into old age [4-6]. A large cohort of UK women study has 82 
shown that the relative risk (RR) of hip fracture in postmenopausal women is 83 
significantly higher than in premenopausal women with similar age (adjusted RR 2.22, 84 
95% confidence interval [CI] 1.22–4.04; p = 0.009) [7]. Menopause is also thought to 85 
be a risk factor for cardiovascular disease in women. The Framingham Heart Study 86 
reported that postmenopausal women aged 50–59 years had 4 times the 10-year 87 
incidence of coronary heart disease as premenopausal women of similar age, but results 88 
were not adjusted for age or smoking [8]. The Nurses’ Health Study reported that 89 
women who had undergone bilateral oophorectomy showed an increased risk of 90 
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coronary heart disease compared to premenopausal women (rate ratio, 2.2; 95 percent 91 
confidence limits, 1.2 and 4.2) [9]. Interestingly, recent studies have reported elevated 92 
risk factors for cardiovascular disease including body fat composition [10], lipids and 93 
lipoprotein [11], and vascular remodeling [12-13] in women transitioning though the 94 
menopause. Increased susceptibility to osteoporosis and cardiovascular disease in 95 
postmenopausal (see Glossary) women may be associated with changes in their 96 
hormone levels. 97 
 98 
The role of FSH in gonadal development and beyond 99 
FSH belongs to the pituitary glycoprotein hormone family, which also includes 100 
luteinizing hormone (LH), chorionic gonadotropin and thyroid-stimulating hormone. 101 
These four hormones share a common α subunit, which forms a functional heterodimer 102 
with a hormone-specific β subunit. FSH primarily exerts its biological function through 103 
binding to the FSH receptor (FSHR), which is predominantly expressed by granulosa 104 
cells in the ovary and sertoli cells in the testes, respectively [14]. Similar to other 105 
glycoprotein hormones, glycosylation of FSH plays an important role in regulating it’s 106 
activity [15] (see Box1). Classically, FSH plays an essential role in gonadal 107 
development, maturation and function. In females, it promotes growth and maturation 108 
of ovarian follicles and estrogen production, whereas in males it supports 109 
spermatogenesis [23]. Through binding to FSHR coupled with different partners, FSH 110 
activates multiple downstream signaling pathways (see Box2, Figure 2).   111 
 112 
Expression of FSHR determines the targets and extent of its biological action. 113 
Traditionally, FSHR is considered to be gonad-specific. A number of reports have 114 
recently demonstrated that it is also expressed in a range of extragonadal sites, including 115 
human osteoclasts [31] and monocytes [32], tumor vasculature and metastases [33], the 116 
liver [34] and human umbilical vein endothelial cells (HUVECs) [35, 36], although 117 
other independent investigators have not been successful in reproducing the original 118 
experiments conducted in HUVECs [37]. These data have prompted researchers to 119 
study the extragonadal effects of FSH and in particular its potential actions in 120 
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postmenopausal women, who show increased risk of osteoporosis and cardiovascular 121 
disease. The decline of estrogen across the period of menopausal transition has 122 
previously been considered as a major contributor of postmenopausal osteoporosis and 123 
cardiovascular disease [38, 39], however recent studies suggest that FSH may also play 124 
an important role. In the present review, we will discuss the latest insights into the 125 
potential pathological roles of FSH in menopausal women that exceed its classical 126 
gonadal regulatory role and examine the underlying mechanisms through which FSH 127 
may promote osteoporosis and cardiovascular disease.   128 
 129 
FSH and the risk of osteoporosis 130 
Postmenopausal women are the majority of patients who suffer from osteoporosis. 131 
Estrogen deficiency has long been considered as a major contributor of postmenopausal 132 
osteoporosis [40]. However, it has been reported that bone loss occurs around 2–3 years 133 
before the FMP [41], when estrogen levels are relatively normal while FSH levels are 134 
significantly elevated (Figure 1). In addition, previous cross-sectional [42] and 135 
longitudinal [43] studies have shown that higher serum FSH levels but not lower serum 136 
estradiol levels are associated with lower bone mineral density among pre- and early 137 
perimenopausal women enrolled in SWAN. Thus, estrogen deficiency cannot fully 138 
explain postmenopausal osteoporosis and FSH may play additional roles in bone loss 139 
during menopause.  140 
 141 
Several observational studies have confirmed the association between FSH levels and 142 
bone metabolism. A small cohort study has shown that women with hypergonadotropic 143 
amenorrhea (mean FSH>40 mIU/mL) have lower lumbar spine bone density than 144 
those with hypogonadotropic amenorrhea (mean FSH<40 mIU/mL), with comparable 145 
estrogen levels between the two groups. In addition, only FSH levels were negatively 146 
correlated with lumbar spine bone density in hypergonadotropic amenorrheic women, 147 
after adjustment for age and body mass index (BMI) [44]. Furthermore, previous studies 148 
investigated 2,375 pre and early perimenopausal women from SWAN and found that 149 
higher FSH concentrations were associated with elevated concentrations of the bone 150 
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resportion marker urinary N-telopeptide of type I collagen (NTx), after adjustment for 151 
BMI, thyroid disease, insulin sensitivity, difficulty in paying for basics, race/ethnicity, 152 
seasonality and site. Higher FSH concentrations were also associated with higher 153 
osteocalcin concentrations (bone formation maker), after adjustment for smoking, 154 
physical activity, physical functioning, BMI, diabetes, insulin sensitivity, thyroid 155 
disease, race and site [45]. A significant association between bone loss and high serum 156 
FSH has also been reported in Chinese women [46, 47]. Unexpectedly, Gourlay et al 157 
have reported that neither FSH nor estrogen shows a strong correlation with bone mass 158 
in younger postmenopausal women [48]. These data may be due to the relative small 159 
size of patient cohorts and/or study designs. Taken together, these data suggest that FSH 160 
is a marker for bone loss in women during menopausal transition, and may directly 161 
promote bone resorption. 162 
  163 
The underlying mechanisms through which osteoporosis occurs is primarily determined 164 
by an imbalance between bone formation and bone resorption [49]. Osteoclasts are the 165 
cells responsible for bone resorption. Sun et al reported increased bone mass and 166 
decreased osteclastic resorption in haploinsufficient FSHβ+/− mice with normal ovarian 167 
function yet 50% reduction in serum FSH levels [50], suggesting that the effect of FSH 168 
on bone is estrogen independent. Further studies reported that FSH activates MEK/Erk, 169 
NF-κB, and Akt signaling pathways through a Gi2α protein-coupled FSHR and directly 170 
accelerates osteoclast formation, function and survival [50-52]. Additionally, FSH also 171 
indirectly stimulates osteoclast formation by inducing inflammatory cytokine release 172 
by immune cells, such as IL-1β, IL-6 and TNF-α [53, 54] (Figure 3). Indeed, Iqbal et al 173 
found that FSH stimulated bone marrow granulocytes and macrophages to release TNF-174 
α, which expanded the number of bone marrow osteoclast precursors and enhanced 175 
osteoblast formation, subsequently leading to the high turn-over bone loss [53]. Having 176 
noted the potential role of FSH in postmenopausal bone loss, several studies have been 177 
performed to test whether the specific inhibition of FSH can prevent ovariectomy-178 
induced bone loss in mouse models. Indeed, blocking FSH with a specific antibody 179 
targeting its β-subunit increases bone mass and reduces body fat in mouse models [55, 180 
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56]. Interestingly, further studies have shown that serum levels of FSH are positively 181 
correlated with the bone resorption marker CTX and the bone formation marker 182 
osteocalcin in healthy postmenopausal women [57], indicating a potential role of FSH 183 
in bone turnover. In addition, a significantly positive association between FSH and CTX 184 
has also been reported in osteoporotic Chinese women during the menopausal transition 185 
[58]. These studies suggest that targeting FSH may be a potential therapeutic target for 186 
the clinical treatment and management of postmenopausal osteoporosis and obesity. 187 
 188 
FSH and the risk for cardiovascular disease 189 
Until recently, it has been widely accepted that the risk of cardiovascular disease 190 
significantly increases in postmenopausal women, with the reduction in estrogen levels 191 
associated with menopausal transition considered to be a major contributor [59]. 192 
Whether estrogen replacement therapy could reduce cardiovascular disease remains 193 
ambiguous. Previous studies have shown that estrogen replacement therapy at standard 194 
daily dose of 0.625mg or less decreases cardiovascular disease risk in postmenopausal 195 
women without previous history of heart disease. However, estrogen at a higher daily 196 
dose of 0.625mg or more and in combination with progestin may modestly increase the 197 
risk for stroke [60, 61]. Recent clinical trials have demonstrated that menopausal 198 
hormone therapy for 5 to 7 years is not associated with risk of all-cause, cardiovascular, 199 
or cancer mortality among 27,347 postmenopausal women aged 50 to 79 years during 200 
a cumulative follow-up of 18 years [62]. In contrast to the decline in estrogen levels 201 
observed during menopausal transition, FSH levels rise sharply and may also contribute 202 
to increased risk of cardiovascular disease following the menopause (Figure 1). Several 203 
previous studies have examined associations between FSH levels and subclinical 204 
atherosclerosis including coronary artery calcium and the carotid intima-media 205 
thickness (IMT) in women, with the majority of them reporting a positive correlation 206 
[63-65]. However, in contrast with this observation, a recent study which included 207 
2,658 Chinese postmenopausal women showed that serum FSH levels were negatively 208 
associated with 10-year risk of cardiovascular disease [66]. Such differences are likely 209 
related to distinct patient cohorts, baseline eligibility criteria, race, age and experimental 210 
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designs. Interestingly, a recent SWAN study evaluated the impact of the entire midlife 211 
course of hormonal trajectories on the risk of atherosclerosis after menopause, which 212 
suggested that women with a lower FSH rise over their menopause transition may be at 213 
lower risk of atherosclerosis than those with a medium or high FSH rises [67]. This 214 
study suggests that it may be much more important to examine the correlation between 215 
FSH trajectory and cardiovascular disease and osteoporosis, rather than ascribe risk to 216 
a single assessment of hormone at a single time point. 217 
 218 
Potential mechanisms by which FSH increases risk of cardiovascular disease 219 
FSH may increase risk of cardiovascular disease through a number of distinct 220 
mechanisms (Figure 4):  221 
Effects of FSH on endothelial cell activation and atherosclerosis 222 
Endothelial cell activation by oxidized lipids and pro-inflammatory stimuli plays an 223 
important role in the initiation and progression of atherosclerosis. Activated endothelial 224 
cells express a variety of adhesion molecules such ICAM-1 and VCAM-1, which 225 
recruits leukocytes to the endothelium [68]. Our recent report demonstrated for the first 226 
time that FSH directly accelerates atherosclerosis in ovariectomized ApoE-/- mice, 227 
independent of estrogen deficiency. Mechanistically, FSH up-regulated VCAM-1 228 
expression in human umbilical vein endothelial cells and subsequently increased human 229 
monocyte adhesion through FSHR/Gαs/cAMP/PKA and PI3K/Akt/mTOR/NF-κB 230 
signaling pathways. Interestingly, FSHR was specifically localized in caveolae of 231 
endothelial cells. Caveolin-1, the main protein component of caveolae, directly 232 
interacted with FSHR and mediated its downstream signaling actions [36].  233 
 234 
FSH accelerates adiposity and lipid accumulation 235 
Cui et al recently reported that FSH treatment increases the weight of abdominal fat 236 
and lipid accumulation of adipocytes in chickens, through enhancing the expression of 237 
genes in the fatty acid metabolism pathway, retinol metabolism pathway, and 238 
peroxisome proliferator-activated receptor (PPAR) signaling pathway [69]. Further 239 
studies showed that FSHR was functionally expressed in human and mouse fat tissues 240 
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and adipocytes. FSH treatment increased lipid biosynthesis, lipid droplet formation, 241 
altered the secretion of leptin and adiponectin through the Gαi/Ca2+/CREB pathway in 242 
mouse 3T3-L1 preadipocytes [70]. Interestingly, recent elegant studies performed by 243 
Liu et al have shown that blockade of FSH signaling with a specific antibody reduces 244 
high-fat diet-induced obesity in wild type mice and adiposity in ovariectomized mice 245 
[55]. Specifically, antibody-treated mice showed significantly reduced total (TFV), 246 
subcutaneous (SFV) and visceral fat volume, but interscapular brown adipose tissue 247 
remained unchanged [55]. These data suggest that FSH may play an important role in 248 
determining body fat distribution, which may contribute to cardiovascular dysfunction 249 
[71]. Interestingly, it has been shown that serum FSH levels are positively associated 250 
with serum total cholesterol and LDL-C levels in Chinese postmenopausal women [34]. 251 
FSH administration in ovariectomized mice promotes dyslipidemia through inhibiting 252 
hepatic cholesterol metabolism. Mechanistically, FSH reduces LDLR levels in 253 
hepatocytes and attenuates the endocytosis of LDL-C, leading to an elevated circulating 254 
LDL-C level [34], which is an independent risk factor for atherosclerosis. Taken 255 
together, these studies suggest that FSH may increase risk factors for cardiovascular 256 
disease through accelerating adiposity and lipid accumulation. 257 
 258 
FSH promotes angiogenesis 259 
Angiogenesis inhibition through the application of endostatin or TNP-470 has been 260 
shown to decrease plaque formation and intimal neovascularization in ApoE-/- mice [72]. 261 
FSH signaling through FSHR in HUVECs promotes angiogenesis, which is 262 
independent of VEGF [73]. Interestingly, treatment of HUVECs with FSH stimulated 263 
the PI3K/AKT signaling pathway, with similar efficacy as VEGF [73]. These data 264 
suggest that FSH may increase atherosclerosis through promoting angiogenesis. 265 
However, the effect of FSH on angiogenesis cannot be reproduced by other 266 
investigators and the discrepancy remains to be clarified [37]. 267 
 268 
Potential role of FSH in vascular calcification.  269 
Vascular calcification is a common feature of advanced atherosclerosis and is important 270 
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in determining atherosclerotic plaque stability [74]. We and others have previously 271 
demonstrated that vascular calcification shares many similarities to bone remodeling, 272 
which involves maintaining a balance between osteoblasts and osteoclasts [75-77]. The 273 
presence of osteoclast-like cells and active resorption of ectopic mineral deposition 274 
have been reported in calcified atherosclerotic plaques [78]. Furthermore, monocytes 275 
and macrophages are frequently observed in atherosclerotic plaque [79]. These data 276 
suggest that osteoclasts, through a signaling cascade involving FSH (Figure 3) may be 277 
recruited to calcified regions where they can resorb mineral deposition, subsequently 278 
increasing the incidence of plaque rupture [80] (Figure 4). In addition, FSH stimulates 279 
immune cells to release inflammatory cytokines [53, 54], which may also contribute to 280 
vascular calcification (Figure 4).  281 
 282 
Clinical use and long-term safety of recombinant FSH therapies against 283 
cardiovascular disease and osteoporosis 284 
There are currently three commercially available recombinant human FSH therapies, 285 
namely Gonal-F, Puregon and Elonva. They are normally prescribed for women with 286 
subfertility who require assisted reproductive technology. Whether treatment with these 287 
medications has long-term safety issues is still under considerable debate. A previous 288 
study showed that there is no association between successful fertility treatment using 289 
FSH and increased risk of cardiovascular disease later in life [81]. However, several 290 
recent studies have suggested that following fertility therapy women may have an 291 
increased risk of long term adverse cardiovascular events, such as hypertension and 292 
stroke [82, 83]. To our knowledge, there are no data about fertility treatment using 293 
recombinant FSH therapies and the long-term risk of osteoporosis in women to date, 294 
and requires future interrogation in the future. Given the current high demand for 295 
fertility treatment, a greater understanding of the long-term risks of fertility treatment 296 
is essential for the development of clinical strategies targeting osteoporosis and 297 
cardiovascular risk reduction.  298 
 299 
Concluding remarks and future perspectives 300 
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In the current review, we have highlighted our current understanding of the potential 301 
pathological roles for FSH in women. Epidemiological and animal studies have 302 
revealed that FSH contributes to the decline in bone health in women undergoing 303 
menopausal transition. Emerging data has shown that FSH treatment enhances 304 
atherosclerotic plaque formation in ovariectomized AopE-/- mice [36]. However, our 305 
understanding of the molecular mechanisms through which FSH increases the risk of 306 
osteoporosis and cardiovascular disease is far from complete (see outstanding 307 
questions). The vast technological advancements such as Next-Generation Sequencing 308 
will provide valuable new information on the molecular pathophysiology of FSH in 309 
extragonadal tissues, such as bone and blood vessels. Animal studies have shown that 310 
blocking FSH increases bone mass, reduces body fat and induces thermogenic adipose 311 
tissue. These data suggest that blocking FSH may not only be a potential opportunity 312 
for treating osteopososis, but also of benefit in the treatment of visceral fat associated 313 
diseases such as metabolic syndrome and cardiovascular disease [55]. Whether FSH 314 
promotes osteoporosis and cardiovascular disease in women remains to be further 315 
elucidated in humans. In conclusion, a fuller understanding of the molecular 316 
pathological roles of FSH for osteoporosis and cardiovascular disease in 317 
postmenopausal women could have significant importance in improving diagnosis, 318 
management and treatment of these major diseases. 319 
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Box1. The regulation of FSH production and its activity 
FSH is composed of a common α subunit and a hormone-specific β subunit, which 
are non-covalently associated. It is only biologically active when these two subunits 
are fused together [16]. FSH levels are strictly controlled by the hypothalamic 
pituitary gonadal axis and sex hormone-mediated negative feedback. In response to 
gonadotropin-releasing hormone from the hypothalamus, pituitary gonadotrophs 
produce FSH and LH [17], which exert their primary function in the gonads. In the 
ovary, FSH stimulates the expression of aromatase, which converts androgens to 
estrogens and induces follicular maturation. In the testes, it acts together with 
testosterone to support spermatogenesis [18]. The estrogens in females and 
androgens in males feedback to the hypothalamus and pituitary, and suppress the 
production of FSH [19]. In addition, previous studies have shown that inhibin A and 
B also inhibits the production of FSH in a manner of negative feedback [20, 21]. 
Similar to other glycoprotein hormones, FSH has various glycosylation variants 
with differential oligosaccharide composition, which contribute nearly 30% of the 
FSH mass and are located in both the α and β subunits [22]. Differential 
glycosylation of FSH modulates its function, including folding, intracellular 
trafficking, secretion, receptor binding, heterodimer stability and cell signaling [15].  
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Box2. FSH intracellular signaling pathways 
It is now well recognized that upon FSH binding, the activated FSHR triggers 
a number of intracellular signaling pathways either in parallel or sequentially. 
Classically, upon FSH activation, FSHR functionally couples to Gαs subunit 
and induces the cAMP/PKA signaling pathway, subsequently activating the 
cAMP regulatory element-binding protein (CREB) and modulating gene 
expression, such as aromatase and inhibin-α [24]. This canonical signaling 
pathway plays a key role for its biological actions inside granulosa cells in the 
ovary and sertoli cells in the testes. It is now clear that FSHR also involves 
other transduction mechanisms upon FSH binding. In recent years, a number of 
Gαs-independent transduction mechanisms have been found. It has been 
reported that FSHR also couples to Gαi [25], Gαq [26], β-arrestins [27], 
Adapter protein containing the Pleckstrin homology domain, the 
Phosphotyrosine binding domain, and the Leucine zipper motif (APPL) [28-
30]. These FSHR interacting partners enable FSH to activate alternative 
signaling pathways, including those mediated by distinct kinases such as 
inositol trisphosphate (IP3), Akt and ERK1/2. This complex signaling network 
triggered by FSH fine-tunes its biological action and determines the fate of 
target cells (Figure 2).  
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Glossary 
Amenorrhea: the absence of a menstrual period in a woman of reproductive age. 
 
Bone resorption: the process that osteoclasts resorb bone tissue and release the 
minerals. 
 
Caveolae: the small invaginations of the plasma membrane of cells, belonging to a 
special type of lipid raft. 
 
Menopausal transition (STRAW +10 Staging System: Stages -2 to -1) [ref. 1] 
Early menopausal transition (Stage –2): Criterias include increased variability in 
menstrual cycle length, a persistent difference of 7 days or more in the length of 
consecutive cycles, elevated but variable FSH levels, low antimüllerian hormone 
and antral follicle count. 
Late menopausal transition (Stage –1): Criterias include the occurrence of 
amenorrhea of 60 days or longer, elevated FSH levels greater than 25 mIU/mL, low 
antimüllerian hormone and antral follicle count, and vasomotor symptoms (likely). 
 
Perimenopause (STRAW +10 Staging System: stage -2 to +1a): the time around 
menopause and begins at Stage –2 and ends 12 months after the final menstrual 
period (Stage +1a). 
 
Postmenopause (STRAW +10 Staging System: Stage +1a, +1b, +1c, +2): The 
time after the final menstrual period.   
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Figure legends 557 
Figure 1. Ovarian hormonal changes in perimenopause. With transition into 558 
menopause, FSH increases markedly and estrogen declines. In postmenopausal women, 559 
estrogen levels are low, and FSH levels remain high for several years [2]. This graph is 560 
intended to show the trends of changes in FSH and Estrogen levels and do not stand for 561 
absolute amounts. 562 
 563 
Figure 2. Multiple intracellular signaling pathways induced by FSH. Classically, 564 
upon FSH binding, the activated FSHR induces canonical Gαs/cAMP/PKA signaling 565 
pathway, which subsequently activates CREB and regulates target gene expression. 566 
FSHR also activates its downstream signaling pathways through other Gαs-independent 567 
transduction mechanisms mainly coupling to other Gα subunits, β-arrestin-dependent 568 
signaling, EGFR transactivation, and APPL1-mediated signals [24-30]. 569 
 570 
Figure 3. FSH accelerates bone resorption through increasing osteoclast formation. 571 
FSH directly enhances RANK expression in monocytes [50-52]. RANKL released by 572 
osteoblasts or T cells binds to RANK in monocytes and promotes osteoclasts formation. 573 
FSH also stimulates monocytes and macrophages to release inflammatory cytokines 574 
such as TNFα, IL1β and IL6 [53-54]. These inflammatory cytokines stimulate 575 
osteoblasts and T cells to secrete RANKL, which promotes osteoclasts formation. 576 
Osteoclasts are the cells responsible for bone resorption, and osteoblasts are the cells 577 
for bone formation. Increased ration of osteclasts to osteoblasts leads to bone mineral 578 
loss, which may subsequently cause osteoporosis [49].  579 
 580 
Figure 4. The potential mechanisms through which FSH accelerates 581 
atherosclerosis. FSHR is expressed by endothelial cells. FSH induces the expression 582 
of vascular cell adhesion molecule 1 (VCAM-1), which recruits monocytes from 583 
circulation [36]. The recruited monocytes migrate and differentiate into macrophages. 584 
Lipid accumulates within these macrophages, leading to foam cell formation. 585 
Macrophage-derived foam cells contribute to the initiation, development and 586 
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progression of atherosclerosis. In addition, the recruited monocytes may also 587 
differentiate into osteoclasts, which can resorb the calcified region and contribute to 588 
plaque instability. Moreover, FSH may stimulate monocytes and T cells to release 589 
inflammatory cytokines such as TNFα, IL1β, IL6 [53-54], leading to chronic 590 
inflammation, which may promote atherosclerosis and vascular calcification. 591 
 592 
Outstanding questions 
Do other bone or vascular cells express FSHR, such as osteoblasts, osteocytes, vascular 
smooth muscle cells, adventitial cells and cardiomyocytes? What are the effects of FSH on 
these cells? 
 
Are there any other downstream genes or signaling pathways activated by FSH in bone cells 
or cardiovascular cells responsible for its effects on osteoporosis and cardiovascular disease? 
 
Do osteoclast or vascular endothelial cell specific FSHR conditional knockout mice 
demonstrate improved bone and vascular health? 
 
Are there any other mechanisms involved in FSH enhanced atherosclerosis in ovariectomized 
ApoE-/- mice such as induction of inflammation or foam cell formation? 
 
FSH blocking increases bone mass and reduces body fat in mouse models. Can these findings 
be translated into humans?   
 
Are there any potential mechanisms for FSH biological activities without binding to FSHR in 
extragonodal tissues? 
 
What are the effects of glycosylation state of FSH on its actions in extragonadal tissues? 
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